The Board of Directors of Kedrion SpA has nominated Val Romberg from the United States as the new CEO of the Company.
Mr. Romberg has accrued in-depth expertise in the pharmaceutical sector and in particular in the field of plasma-derivatives. His most recent position was that of Executive Vice President of Operations of CSL, the world leader in plasma-derivatives.
With a formal training in chemistry, he has also held important positions in the field of research and development and has worked for important Groups, including West Pharmaceutical Services and Aventis Behring.
Paolo Marcucci, the President of Kedrion, who will be responsible for the mandates in strategy, business development and institutional relations, commented: “I am extremely pleased that Val has accepted our proposal. His expertise and prestige within the plasma-derivatives industry are the best guarantee for managing the challenges laid out in our strategic plans and for ensuring that our company will continue to grow in the future”.
In a statement, the new CEO declared: “I am pleased to become a part of the Kedrion Group, which produces and distributes important medicines and treatments for patients worldwide. Furthermore, I am particularly enthusiastic to be able to follow the project of an anti Covid-19 therapy, which Kedrion is developing alongside its research partner Columbia University Irving Medical Center in New York and the Israeli company Kamada”.
Marcucci further commented: “The road which Kedrion embarked upon many years ago envisages a strong drive towards internationalization in markets such as the USA, and a responsibility towards Italy and its health system. Val Romberg upholds this course and has the total support of the Board of Directors and all of Kedrion’s shareholders. It will be stimulating to work alongside him, facing this new season of our company together”.